  |
 | Up a level |
Pivot, Xavier B and Bondarenko, Igor and Dvorkin, Mikhail and Trishkina, Ekaterina and Ahn, Jin-Hee and Im, Seock-Ah and Sarosiek, Tomasz and Chattopadhyay, Sanjay and Wojtukiewicz, Marek and Moiseyenko, Vladimir and Shparyk, Yaroslav V and Bello, Maximino De Guzman and Semiglazov, Vladimir and Song, Sujeong and Lim, Jae Yun (2017) A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer. Journal of Clinical Oncology, 35 (15). p. 509. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
Robertson, John F R and Bondarenko, Igor M and Trishkina, Ekaterina and Dvorkin, Mikhail and Panasci, Lawrence and Manikhas, Alexey and Shparyk, Yaroslav and Cardona-Huerta, Servando and Cheung, Kwok-Leung and Philco-Salas, Manuel Jesus and Ruiz-Borrego, Manuel and Shao, Zhimin and Noguchi, Shinzaburo and Rowbottom, Jacqui and Stuart, Mary and Grinsted, Lynda M and Fazal, Mehdi and Ellis, Matthew J (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet, 388 (10063). pp. 2997-3005. ISSN 1474-547X
